While stringent guidelines are available for the use of NST in triple-negative and HER2+ breast cancer, the presented data show the need for the development of and adherence to such well-defined recommendations also for patients with HR+/HER2-breast cancer. This evidence concerns the gene HR and breast carcinoma.